Eliminated were holdings in materials and utilities. Strategies Portfolio additions: consumers, financials and healthcare
Retrophin's promising drug pipeline could boost shares. Strategies Why I’m bullish on biotech firm Retrophin
Insulated from the dollar, mid-cap companies are thriving. Strategies Why mid-cap stocks reigned in the first quarter
The mighty dollar is taking its toll on corporate earnings. Strategies The incredible heaviness of the dollar
Here's why the US and Hong Kong markets are highly correlated. Strategies Why the Hong Kong rally is bullish for US stocks
M&A deals are expanding worldwide. Here's how to play it. Outlook How to profit from the merger mania
Job growth is slow and the manufacturing sector isn't expanding. Strategies The US stock market is stuck in a rut
Rebounding consumer spending trumps the strong dollar. Strategies The American consumer to the rescue
First quarter earnings are shaping up to be the weakest since 2009. Outlook US corporate earnings run off the rails
Energy stocks are trading 20%-50% discounts to their 2014 highs. Strategies Looking for value? Check out energy stocks
Think US stocks are pricey? Check out what's happening in China. Outlook 5 signs the Chinese stock market is bubbly
Brazil's central bank should ride to rescue as it did in 2002. Strategies The optimist’s case for Brazil
